Citations 12
A Risk-Adapted Study to Assess the Efficacy of Enasidenib and Subsequent Response-Driven Addition of Azacitidine for Newly Diagnosed IDH2-Mutant AML Patients: 3-Year Follow-up
Stein, Eytan M. , Huang, Ying , Dunbar, Andrew , Baer, Maria R. , Kovacsovics, Tibor , Blum, William , Schiller, Gary J. , Olin, Rebecca L. , Foran, James M. , Litzow, Mark R. , Patel, Prapti A. , Boyiadzis, Michael , Collins, Robert H. , Chervin, Jordan , Vergilio, Jo‐Anne, Heerema, Nyla A. , Rosenberg, Leonard, Yocum, Ashley O. , Druggan, Franchesca , Marcus, Sonja, Stefanos, Mona , Martycz, Molly , Borate, Uma , Burd, Amy , Byrd, John C. , Byrd, John C , Cai, Sheng F , Stock, Wendy , Lin, Tara L. , Foster, Matthew C , Shoben, Abigail B. , Chen, Timothy Frank , Druker, Brian J , Mims, Alice S , Levine, Ross L.
Blood | November 28, 2022 | Volume: 140 | Issue: Supplement 1 | Pages: 2016-2019
Entospletinib (ENTO) in Combination with Cytarabine (Ara-C) and Daunorubicin (DNR) in Newly Diagnosed (ND) Adult Patients with NPM1-Mutated and FLT3-ITD Wild-Type Acute Myeloid Leukemia (AML) Is Associated with Good Response and Survival: A P
Borate, Uma , Li, Rui , Huang, Ying , Swords, Ronan , Stein, Eytan M. , Foran, James M. , Baer, Maria R. , Odenike, Olatoyosi , Patel, Prapti A. , Collins, Robert H. , Kovacsovics, Tibor , Deininger, Michael W. , Olin, Rebecca L. , Arellano, Martha , Blum, William , Schiller, Gary J. , Boyiadzis, Michael , Redner, Robert L. , Al‐Mansour, Zeina , Curran, Emily , Heerema, Nyla A. , Gana, Theophilus J. , Martycz, Molly , Rosenberg, Leonard, Marcus, Sonja, Yocum, Ashley O. , Stefanos, Mona , Druggan, Franchesca , Burd, Amy , Byrd, John C. , Byrd, John C , Traer, Elie , Duong, Vu H. , Stock, Wendy , Madanat, Yazan F. , Smith, Catherine C. , Lin, Tara L. , Foster, Matthew C , Chen, Timothy Frank , Levine, Ross L. , Druker, Brian J , Mims, Alice S
Blood | November 28, 2022 | Volume: 140 | Issue: Supplement 1 | Pages: 6200-6203